Chemotherapy Combined With Apatinib and PD-1 Antibody
NCT05025033
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
Sponsor
Tianjin Medical University Cancer Institute and Hospital